 SOUTH PLAINFIELD, N.J., May 26, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced that both the United States Food and Drug Administration FDA and European Commission EC have granted Orphan Drug Designation ODD for PTC923 for the treatment of patients with hyperphenylalaninemia. 